PFE · 10-Q · 2026Q2 · Full report

Regulatory Risk

PFIZER INC · 2026-08-04 · Importance 37 · Surprise 42

Pfizer continues to monitor U.S. implementation of the Inflation Reduction Act, including the Medicare Drug Price Negotiation Program and government-set Maximum Fair Prices. The MFP for Eliquis became effective January 1, 2026, while negotiated prices for Ibrance and Xtandi become effective in 2027; Xeljanz remains selected through 2028 but will not receive an MFP because CMS determined bona fide generic marketing exists. Pfizer also stated that changes to Medicaid rebates or the 340B Program could materially affect its business, while it does not expect an incremental 2026 impact from the Medicare Part D redesign versus the 2025 baseline.

Key facts

• Approvals in May–July 2026 include Veppanu (May 2026 U.S.), Hympavzi (May 2026 EU; June 2026 U.S. for pediatric 6–<12), Braftovi in combination (June 2026 EU), Ibrance combination maintenance (June 2026 U.S.), Padcev neoadjuvant/adjuvant (June 2026 EU; July 2026 U.S.), and Comirnaty 2026-2027 Formula JN.1 (July 2026 EU). source
• Pfizer identifies risk that the IRA Medicare Part D Redesign may have anticipated impacts on its business and is included in its forward-looking considerations. source